Head-to-Head
Peptide comparisons, by the evidence
Independent side-by-side comparisons: which compound the research favors, for whom, and where the honest caveats are.
Semaglutide vs Tirzepatide
AFDA-ApprovedvsAFDA-Approved
Tirzepatide produced larger weight loss in trials, including the head-to-head SURMOUNT-5 (20.2% vs 13.7%); semaglutide has the longer cardiovascular-outcomes record and a daily pill for weight loss. An independent, evidence-based comparison.
BPC-157 vs TB-500
DPreclinical OnlyvsDPreclinical Only
BPC-157 has extensive animal data and a handful of small human studies; TB-500 has almost no direct evidence of its own, borrowing its reputation from its parent protein, thymosin beta-4. Neither is FDA-approved. An FDA advisory panel recommended both for compounding in July 2026; FDA has not decided.